Hypoxia Signaling in Human Health and Diseases: Implications and Prospects for Therapeutics
Overview
Pharmacology
Authors
Affiliations
Molecular oxygen (O) is essential for most biological reactions in mammalian cells. When the intracellular oxygen content decreases, it is called hypoxia. The process of hypoxia is linked to several biological processes, including pathogenic microbe infection, metabolic adaptation, cancer, acute and chronic diseases, and other stress responses. The mechanism underlying cells respond to oxygen changes to mediate subsequent signal response is the central question during hypoxia. Hypoxia-inducible factors (HIFs) sense hypoxia to regulate the expressions of a series of downstream genes expression, which participate in multiple processes including cell metabolism, cell growth/death, cell proliferation, glycolysis, immune response, microbe infection, tumorigenesis, and metastasis. Importantly, hypoxia signaling also interacts with other cellular pathways, such as phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) signaling, nuclear factor kappa-B (NF-κB) pathway, extracellular signal-regulated kinases (ERK) signaling, and endoplasmic reticulum (ER) stress. This paper systematically reviews the mechanisms of hypoxia signaling activation, the control of HIF signaling, and the function of HIF signaling in human health and diseases. In addition, the therapeutic targets involved in HIF signaling to balance health and diseases are summarized and highlighted, which would provide novel strategies for the design and development of therapeutic drugs.
Hypoxemia exerts detrimental effects on the choroid plexuses and cerebrospinal fluid system in rats.
Barakat R, Al-Sarraf H, Redzic Z Fluids Barriers CNS. 2025; 22(1):27.
PMID: 40075475 PMC: 11905537. DOI: 10.1186/s12987-024-00613-w.
Yu H, Wang B, Li Z, Liu K, Chen W, Zhao S Mater Today Bio. 2025; 31:101585.
PMID: 40070869 PMC: 11893380. DOI: 10.1016/j.mtbio.2025.101585.
Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy.
Zhang J, Wang F, Sun Z, Ye J, Chu H J Nanobiotechnology. 2025; 23(1):161.
PMID: 40033359 PMC: 11874808. DOI: 10.1186/s12951-025-03236-x.
van der Mescht M, Steel H, Anderson R, Rossouw T Front Cell Infect Microbiol. 2025; 14:1458195.
PMID: 40008234 PMC: 11850333. DOI: 10.3389/fcimb.2024.1458195.
Podolski-Renic A, Chigriai M, Jovanovic Stojanov S, Grozdanic M, Lupsic E, Nikolic I Pharmaceutics. 2025; 17(2).
PMID: 40006556 PMC: 11859366. DOI: 10.3390/pharmaceutics17020189.